CHICAGO (MedPage Today) -- The combination of ipilimumab and nivolumab may boost response rates against metastatic melanoma without excessive toxicity, a phase I trial showed. via MedPageToday.com - medical news plus CME for physicians Read More Here..
No comments:
Post a Comment